Complement C5a Promotes Epithelial-Mesenchymal Transition in Pterygium via C5aR Activation
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.6.16 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2026. Verfasst von Jiaxin Han und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, People's Republic of China. Hauptthemen laut MEDLINE: Pterygium, Epithelial-Mesenchymal Transition, Receptor, Anaphylatoxin C5a, Complement C5a. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The purpose of this study was to investigate candidate regulatory proteins associated with the pathogenesis of pterygium and to explore their potential biological roles.
Methods
Paired pterygium and conjunctival tissues from the discovery cohort (n = 10) and the validation cohort (n = 3) were subjected to proteomic analysis (label-free/4D label-free) to identify candidate differentially expressed proteins (DEPs). Exploratory clinical correlation and diagnostic analyses of DEPs were performed. Functional validation was conducted using primary conjunctival epithelial cells (PCECs) treated with C5a with or without the C5aR antagonist PMX53. Assays included evaluation of epithelial-mesenchymal transition (EMT) markers (RT-qPCR, Western blot, and immunofluorescence), migration (wound-healing assay), apoptosis (flow cytometry), and VEGFA expression.
Results
Proteomic analysis showed that C5 was consistently upregulated, and upregulated DEPs were significantly enriched in the complement and coagulation cascades. Furthermore, C5 showed a significant positive correlation with vessel density (r = 0.68, P = 0.029) and achieved an area under the curve (AUC) of 0.8 in the discovery cohort. Functional validation demonstrated that C5a promoted EMT-like marker changes in PCECs, including decreased E-cadherin and increased vimentin and fibronectin (FN). C5a treatment was also associated with enhanced cellular migration and reduced apoptosis, and these cellular changes were attenuated by the C5aR antagonist PMX53. Notably, C5a also increased VEGFA expression.
Conclusions
These findings suggest that C5a/C5aR signaling may contribute to pterygium pathogenesis by promoting EMT-related changes in conjunctival epithelial cells, supporting C5aR as a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, People's Republic of China.
- State Key Laboratory of Ophthalmology, Optometry, and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, People's Republic of China.
- Department of Ophthalmology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, People's Republic of China.
- Department of Ophthalmology, Zhejiang Provincial People's Hospital, Zhejiang, People's Republic of China.
Zitieren
APA
Han, J., Gong, Q., Wang, H., Xie, B., Ye, L., Shen, L., & Hu, L. (2026). Complement C5a Promotes Epithelial-Mesenchymal Transition in Pterygium via C5aR Activation. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.6.16
Vancouver
Han J, Gong Q, Wang H, Xie B, Ye L, Shen L, et al. Complement C5a Promotes Epithelial-Mesenchymal Transition in Pterygium via C5aR Activation. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.6.16
BibTeX
@article{Han2026,
author = {Han, Jiaxin and Gong, Qianwen and Wang, He and Xie, Bintao and Ye, Lingying and Shen, Lijun and Hu, Liang},
title = {Complement C5a Promotes Epithelial-Mesenchymal Transition in Pterygium via C5aR Activation},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.6.16}
}
EUVIMED